Effect [qlco]
Combined [qlco]
Estrogen [horm, phsu, strd]
Progesterone [horm, phsu, strd]
hormone replacement [topp]
therapy [ftcn]
Disease [dsyn]
activity [dora]
Lupus Erythematosus, Systemic [dsyn]
randomized [resa]
Trial [resa]
Background [cnce]
Concern [idcn]
Exogenous hormones [horm, orch]
Female [fndg]
worsen [qlco]
Disease [dsyn]
activity [dora]
Women [popg]
Lupus Erythematosus, Systemic [dsyn]
Objective [inpr]
To [qlco]
Evaluate [ftcn]
Effect [qlco]
Hormone replacement therapy [topp]
Disease [dsyn]
activity [dora]
postmenopausal [tmco]
Women [popg]
Lupus Erythematosus, Systemic [dsyn]
Design [acty]
randomized controlled trial [inpr, resa]
DOUBLE BLIND [resa]
placebo [topp]
Conduct [inbe]
setting [ftcn]
University [mnob, orgt]
Affiliated [qlco]
Rheumatology clinic [inpr]
practice [menp]
U S [geoa]
Patients [podg]
Menopausal [phsf]
Patients [podg]
Mean [qnco]
Age [orga]
Inactive [qlco]
Stable [qlco]
Active [ftcn]
Lupus Erythematosus, Systemic [dsyn]
interventions [hlca]
months [tmco]
treatment [ftcn]
Active [ftcn]
Drug [phsu]
mg% [qnco]
Conjugated estrogen [horm, phsu, strd]
Daily [tmco]
Plus [qlco]
mg% [qnco]
Medroxyprogesterone [horm, phsu, strd]
days [tmco]
month [tmco]
placebo [topp]
month [tmco]
Follow-up [fndg]
Rate [acty]
Hormone replacement therapy [topp]
Group [idcn]
placebo [topp]
Group [idcn]
measurements [ftcn]
Primary Endpoint [irda]
occurrence [ftcn]
Severe [qlco]
Flare [sosy]
Defined [cnce]
Safety [hcpp]
Estrogens [horm, phsu, strd]
lupus [dsyn]
national [inpr]
Assessment [hlca]
Composite [qlco]
Result [ftcn]
Severe [qlco]
Flare [sosy]
Rare [tmco]
treatment [ftcn]
Group [idcn]
month [tmco]
Severe [qlco]
Flare [sosy]
Rate [acty]
Hormone replacement therapy [topp]
Group [idcn]
placebo [topp]
Group [idcn]
Estimated [qnco]
P NOS [aapp, imft]
Upper [spco]
limit [ftcn]
Side [spco]
Cl - [elii]
treatment [ftcn]
Margin [spco]
Mild to moderate [qlco]
Flare [sosy]
Increased [qnco]
Hormone replacement therapy [topp]
Group [idcn]
Flare [sosy]
Person [popg]
Hormone replacement therapy [topp]
Flare [sosy]
Person [popg]
placebo [topp]
Relative Risk [qnco]
P NOS [aapp, imft]
Probability [qnco]
Type [qlco]
Flare [sosy]
months [tmco]
Hormone replacement therapy [topp]
Group [idcn]
placebo [topp]
Group [idcn]
P NOS [aapp, imft]
Hormone replacement therapy [topp]
Group [idcn]
Death [orgf]
Stroke [dsyn]
Cases [ftcn]
Deep-Venous Thrombosis [dsyn]
Case [ftcn]
Thrombosis [patf]
Arteriovenous graft [acab]
placebo [topp]
Group [idcn]
Deep-Venous Thrombosis [dsyn]
limitations [ftcn]
findings [ftcn]
Not [ftcn]
Women [popg]
High [qlco]
Titer [qnco]
Antibodies, Anticardiolipin [aapp, imft]
Lupus Anticoagulant [aapp, imft]
Previous [tmco]
Thrombosis [patf]
Conclusions [idcn]
ADD [mobd]
short [qlco]
Course [tmco]
Hormone replacement therapy [topp]
Associated [qlco]
Small [qnco]
Risk [qlco]
Increasing [ftcn]
Natural [ftcn]
Flare [sosy]
Rate [acty]
lupus [dsyn]
Most [qnco]
Flare [sosy]
Mild to moderate [qlco]
Benefits [qnco]
Hormone replacement therapy [topp]
Balanced [ftcn]
Risk [qlco]
Flare [sosy]
Hormone replacement therapy [topp]
Not [ftcn]
Increase [ftcn]
Risk [qlco]
Severe [qlco]
Flare [sosy]
Compared [acty]
placebo [topp]
